Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Ocugen (OCGN) Stock Price & Analysis

OCGN Stock Chart & Stats

MX$15.00MX$0.00(0.00%)
At close:
MXN 15MXN 20MXN 253 Aug18 Aug8 Sep15 Sep29 Sep12 Oct26 Oct
Day’s Range
MXN 12.61 - MXN 15.93
52-Week Range
MXN 12.61 - MXN 45.50
Previous Close
MXN 15.00
Volume
141
Average Volume (3M)
677
Market Cap
MXN 4.48B
Enterprise Value
MXN 506.12M
Total Cash (Recent Filing)
MXN 100.05M
Total Debt (Recent Filing)
MXN 87.99M
Price to Earnings (P/E)
―
Beta
-0.62
Next Earnings
Nov 04, 2026 (Est.)
EPS Estimate
-1.13
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Late-stage Regulatory Progress

FDA clearance and RMAT designation move OCU410 into a registrational development stage with defined filing targets. This regulatory progress can shorten the path toward commercialization, strengthen partnering credibility, and support a broader ophthalmic gene-therapy platform over the next several quarters.

Regional Licensing And Royalty Potential

The Roots agreement creates external validation and a commercial pathway for OCU400 without requiring Ocugen to build all regional infrastructure itself. Upfront payments, milestone economics, royalties, and a supply agreement could diversify future revenue as clinical and regulatory milestones advance.

Extended Development Runway

Funding visibility into 2028 gives Ocugen time to pursue multiple late-stage programs and targeted BLA filings rather than relying solely on near-term partnering or asset monetization. This runway supports clinical execution, manufacturing preparation, and regulatory work across the platform.

Bears Say

Negative Equity And Higher Debt

Negative equity combined with sharply higher debt materially reduces financial flexibility and increases dependence on successful financing or operating milestones. The capital structure may constrain strategic choices, raise refinancing exposure, and leave less capacity to absorb setbacks in development or approval timing.

Persistent Cash Burn

Large operating and free-cash-flow deficits show that Ocugen is not yet self-funding and must continue converting capital into clinical progress before generating durable cash inflows. Sustained burn can consume financing proceeds quickly and increase the importance of milestones, partnerships, or future capital raises.

Unproven Profitability And Commercialization

Revenue remains small relative to the company’s development spending, while persistent negative margins show that commercial-scale profitability has not been demonstrated. Even successful approvals would require reimbursement, patient pathways, and market access execution before the pipeline can produce durable earnings.

Ocugen News

OCGN FAQ

What was Ocugen’s price range in the past 12 months?
Ocugen lowest stock price was Mex$12.61 and its highest was Mex$45.50 in the past 12 months.
What is Ocugen’s market cap?
Ocugen’s market cap is Mex$4.48B.
When is Ocugen’s upcoming earnings report date?
Ocugen’s next earnings report is estimated for Nov 04, 2026 (not yet confirmed), which is in 2 days.
How were Ocugen’s earnings last quarter?
Ocugen released its earnings results on Aug 06, 2026. The company reported -Mex$1.315 earnings per share for the quarter, missing the consensus estimate of -Mex$0.996 by -Mex$0.319.
Is Ocugen overvalued?
According to Wall Street analysts Ocugen’s price is currently Undervalued.
Does Ocugen pay dividends?
Ocugen does not currently pay dividends.
What is Ocugen’s EPS estimate?
Ocugen’s EPS estimate is -1.13.
How many shares outstanding does Ocugen have?
Ocugen has 339,110,400 shares outstanding.
What happened to Ocugen’s price movement after its last earnings report?
Ocugen reported an EPS of -Mex$1.315 in its last earnings report, missing expectations of -Mex$0.996. Following the earnings report the stock price went down -4.444%.
Which hedge fund is a major shareholder of Ocugen?
Currently, no hedge funds are holding shares in MX:OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology